Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + ACP-319 in R/R CLL
NCT02157324Phase 1Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Aug 2014
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in chronic lymphocytic leukemia (CLL) comparing acalabrutinib first with ACP-319 first (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Aug 2014; status: active, not recruiting.
02
Drugs
acalabrutinibAMG-319
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02157324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157324.